Edition:
United Kingdom

Mauna Kea Technologies SAS (MKEA.PA)

MKEA.PA on Paris Stock Exchange

1.61EUR
14 Jun 2019
Change (% chg)

€-0.00 (-0.25%)
Prev Close
€1.61
Open
€1.63
Day's High
€1.63
Day's Low
€1.60
Volume
6,984
Avg. Vol
101,166
52-wk High
€3.44
52-wk Low
€1.41

Latest Key Developments (Source: Significant Developments)

Mauna Kea Technologies Announces Exercise Of A Tranche Of 5 Million Euros With IPF Partners
Wednesday, 29 May 2019 

May 29 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES ANNOUNCES THE EXERCISE OF A TRANCHE OF €5 MILLION DEBT WITH IPF PARTNERS.PART OF AMENDMENT OF DEBT SUBSCRIPTION AGREEMENT SIGNED ON NOVEMBER 13, 2018.SECOND TRANCHE OF EUR 3 MILLION WAS NOT EXERCISED.FIRST TRANCHE OF BONDS WHICH IS NOW EXERCISED HAS A 5-YEAR MATURITY, WITH INTEREST-ONLY PAYMENTS FOR FIRST 15 MONTHS.  Full Article

Mauna Kea Technologies Q1 Sales Up At EUR 1.7 Million
Wednesday, 24 Apr 2019 

April 24 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::Q1 SALES EUR 1.7 MILLION VERSUS EUR 1.0 MILLION YEAR AGO.  Full Article

Mauna Kea Receives 510(k) Clearance For Cellvizio Needle-Based AQ-Flex 19 Confocal Miniprobe
Monday, 25 Feb 2019 

Feb 25 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES RECEIVES 510(K) CLEARANCE FOR THE CELLVIZIO® NEEDLE-BASED AQ-FLEX™ 19 CONFOCAL MINIPROBE™ ENABLING PERIPHERAL LUNG NODULE TARGETING AND IMAGING.CELLVIZIO® AQ-FLEX PROBE IS CLEARED FOR USE WITH TRANSBRONCHIAL NEEDLES THROUGH EXISTING BRONCHOSCOPES AND BRONCHOSCOPIC ACCESSORIES.  Full Article

Mauna Kea Technologies FY Total Revenue Up At 6.8 Million Euros
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::FY TOTAL REVENUE EUR 6.8 MILLION VERSUS EUR 6.7 MILLION YEAR AGO.TOTAL SALES FOR Q4 OF 2018 WERE EUR 2.1 MILLION, UP 37% YEAR-OVER-YEAR.  Full Article

Mauna Kea Technologies Announces Amendment To IPF Partners Debt Agreement
Monday, 19 Nov 2018 

Nov 19 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::ANNOUNCES AMENDMENT TO EXISTING DEBT AGREEMENT WITH IPF PARTNERS.PROVIDES ADDITIONAL BORROWING CAPACITY OF UP TO 10 MILLION EUROS.THE DEBT SUBSCRIPTION AGREEMENT HAS BEEN AMENDED TO INCLUDE TWO ADDITIONAL TRANCHES OF BONDS.FIRST TRANCHE OF BONDS HAS A 5-YEAR MATURITY, WITH INTEREST-ONLY PAYMENTS FOR FIRST 15 MONTHS.THE BONDS BEAR INTEREST AT AN ANNUAL RATE EQUAL TO THE 3-MONTH EURIBOR +8.0%..TRANCHE OF EUR 5.0 MILLION, AVAILABLE IN NEXT 5 MONTHS AND OTHER TRANCHE OF EUR 5.0 MILLION AVAILABLE UNTIL SEPTEMBER 2019.SECOND TRANCHE OF BONDS HAS A 4-YEAR MATURITY, WITH INTEREST-ONLY PAYMENTS FOR 12 MONTHS.  Full Article

Mauna Kea Technologies Q3 Sales Is At 1.9 Million Euros
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES REPORTS THIRD QUARTER 2018 SALES.U.S. CONSUMABLE MINIPROBES SALES UP 38% IN Q3 VERSUS SAME PERIOD LAST YEAR.Q3 GLOBAL SALES UP 4% YEAR-OVER-YEAR, WITH GLOBAL MINIPROBES SALES UP 31%.Q3 SALES EUR 1.9 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.  Full Article

Mauna Kea Technologies Announces First Published Report Of Live "Tele-Cellvizio®" Utilization In Vivo
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES ANNOUNCES FIRST PUBLISHED REPORT OF LIVE "TELE-CELLVIZIO®" UTILIZATION IN VIVO BETWEEN SURGEONS AND REMOTE PATHOLOGISTS.NEW STUDY CONFIRMS THAT CRITERIA IDENTIFIED EX VIVO ARE WELL REPRODUCED IN VIVO.PCLE CLEARLY ALLOWED DIFFERENTIATION OF INFLAMMATORY FROM MALIGNANT TISSUES.  Full Article

Mauna Kea Technologies Announces Positive Results On Cellvizio
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES ANNOUNCED ON WEDNESDAY THE PUBLICATION IN SURGICAL ENDOSCOPY OF POSITIVE RESULTS FROM LARGE U.S. PROSPECTIVE MULTI-CENTER CLINICAL TRIAL ON DETECTION OF BARRETT’S ESOPHAGUS WITH CELLVIZIO®.THERE WAS NO STATISTICALLY SIGNIFICANT DIFFERENCE IN PERFORMANCE BETWEEN NOVICE PCLE USERS AND EXPERT REVIEW..A BLINDED EXPERT REVIEW OF DISCREPANT RESULTS BETWEEN CELLVIZIO AND BIOPSIES CONFIRMED THAT INTESTINAL METAPLASIA DETECTED BY CELLVIZIO WAS INDEED PRESENT IN 56 OF 61 PATIENTS WITH NEGATIVE BIOPSIES.  Full Article

Mauna Kea Technologies H1 Sales Down At 2.7 Million Euros
Wednesday, 25 Jul 2018 

July 25 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::H1 SALES EUR 2.7 MILLION VERSUS EUR 3.3 MILLION YEAR AGO.PRECLINICAL SALES FELL 23% IN H1 2018 COMPARED TO LAST YEAR AT THE SAME PERIOD.  Full Article

Mauna Kea Technologies Obtains FDA Clearance For Applications Of Cellvizio Confocal Laser Endomicroscopy In Neurosurgery
Thursday, 24 May 2018 

May 24 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES OBTAINS FIRST EVER FDA CLEARANCE FOR APPLICATIONS OF CELLVIZIO® CONFOCAL LASER ENDOMICROSCOPY IN NEUROSURGERY.  Full Article